MYO7A_HUMAN,S1105R,0.180,-,-,-
MYO7A_HUMAN,V1107M,0.093,-,-,-
MYO7A_HUMAN,K1128Q,0.367,-,-,-
MYO7A_HUMAN,H1131D,0.463,-,-,-
MYO7A_HUMAN,S1135P,0.475,-,-,-
MYO7A_HUMAN,N1285S,0.159,-,-,-
MYO7A_HUMAN,I1291T,0.660,Altered Metal binding (Pr = 0.20 | P = 0.04); Altered Stability (Pr = 0.09 | P = 0.05), None,-
MYO7A_HUMAN,I1291V,0.187,-,-,-
MYO7A_HUMAN,K1294H,0.669,Altered Metal binding (Pr = 0.26 | P = 8.9e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), ELME000172|ELME000233|PS00005|PS00006,-
MYO7A_HUMAN,S1310V,0.629,Loss of Intrinsic disorder (Pr = 0.34 | P = 0.05); Altered Metal binding (Pr = 0.14 | P = 0.02), ELME000053,-
MYO7A_HUMAN,N1361S,0.137,-,-,-
MYO7A_HUMAN,N1411T,0.388,-,-,-
MYO7A_HUMAN,I1417L,0.542,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000182,-
MYO7A_HUMAN,I1422V,0.292,-,-,-
MYO7A_HUMAN,L1425M,0.183,-,-,-
MYO7A_HUMAN,L1428R,0.636,Altered Transmembrane protein (Pr = 0.21 | P = 4.6e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000233,-
MYO7A_HUMAN,Q1433H,0.373,-,-,-
MYO7A_HUMAN,S1483N,0.275,-,-,-
MYO7A_HUMAN,S1483P,0.637,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.28 | P = 0.01); Loss of Loop (Pr = 0.28 | P = 0.02); Gain of B-factor (Pr = 0.25 | P = 0.04), ELME000004|ELME000063|ELME000155,-
MYO7A_HUMAN,K1486R,0.266,-,-,-
MYO7A_HUMAN,D1488E,0.558,Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03), ELME000002|ELME000335,-
MYO7A_HUMAN,I1516L,0.704,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,V1527I,0.111,-,-,-
MYO7A_HUMAN,L1531R,0.925,Gain of Strand (Pr = 0.26 | P = 0.05), ELME000007|ELME000051|ELME000053|ELME000233,-
MYO7A_HUMAN,G1532Q,0.748,, ELME000007|ELME000051|ELME000053,-
MYO7A_HUMAN,S1534A,0.461,-,-,-
MYO7A_HUMAN,L1536A,0.363,-,-,-
MYO7A_HUMAN,L1536P,0.577,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Stability (Pr = 0.12 | P = 0.03), None,-
MYO7A_HUMAN,L1536V,0.204,-,-,-
MYO7A_HUMAN,A1540S,0.095,-,-,-
MYO7A_HUMAN,P1550L,0.336,-,-,-
MYO7A_HUMAN,P1550M,0.460,-,-,-
MYO7A_HUMAN,A1551T,0.138,-,-,-
MYO7A_HUMAN,D1578E,0.394,-,-,-
MYO7A_HUMAN,N1616S,0.226,-,-,-
MYO7A_HUMAN,A1628V,0.202,-,-,-
MYO7A_HUMAN,N1645S,0.476,-,-,-
MYO7A_HUMAN,N1650S,0.152,-,-,-
MYO7A_HUMAN,N1653S,0.760,Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.04), ELME000063|PS00005,-
MYO7A_HUMAN,Q1690P,0.611,Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Phosphorylation at T1687 (Pr = 0.25 | P = 0.03), ELME000118|ELME000159,-
MYO7A_HUMAN,L1697H,0.378,-,-,-
MYO7A_HUMAN,L1698M,0.098,-,-,-
MYO7A_HUMAN,L1700I,0.083,-,-,-
MYO7A_HUMAN,L1700Q,0.242,-,-,-
MYO7A_HUMAN,V1707A,0.107,-,-,-
MYO7A_HUMAN,V1707P,0.242,-,-,-
MYO7A_HUMAN,A1709S,0.065,-,-,-
MYO7A_HUMAN,E1715Q,0.602,Loss of Phosphorylation at Y1719 (Pr = 0.25 | P = 0.04); Loss of Sulfation at Y1719 (Pr = 0.01 | P = 0.04), ELME000064|ELME000117|ELME000163|ELME000182|ELME000220|PS00006,-
MYO7A_HUMAN,Y1721C,0.515,Loss of Phosphorylation at Y1721 (Pr = 0.46 | P = 5.2e-03); Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 8.7e-03), ELME000120|ELME000182,-
MYO7A_HUMAN,R1723P,0.921,Gain of B-factor (Pr = 0.28 | P = 8.0e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Loss of Phosphorylation at Y1719 (Pr = 0.27 | P = 0.03); Gain of Sulfation at Y1721 (Pr = 0.06 | P = 6.3e-03), ELME000057|ELME000155|ELME000182,-
MYO7A_HUMAN,R1723S,0.799,Gain of Phosphorylation at R1723 (Pr = 0.37 | P = 7.7e-03); Gain of Sulfation at Y1721 (Pr = 0.06 | P = 5.3e-03), ELME000136|ELME000159|ELME000182,-
MYO7A_HUMAN,P1726G,0.598,Gain of Phosphorylation at Y1721 (Pr = 0.26 | P = 0.03); Gain of Acetylation at K1727 (Pr = 0.24 | P = 0.02); Altered Disordered interface (Pr = 0.18 | P = 0.04); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.2e-03), None,-
MYO7A_HUMAN,K1727R,0.444,-,-,-
MYO7A_HUMAN,T1729L,0.548,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Disordered interface (Pr = 0.23 | P = 0.03), ELME000106|ELME000146,-
MYO7A_HUMAN,V1733D,0.751,Altered Disordered interface (Pr = 0.44 | P = 4.7e-03); Gain of Intrinsic disorder (Pr = 0.42 | P = 6.0e-03); Altered Stability (Pr = 0.31 | P = 5.4e-03); Gain of Proteolytic cleavage at V1733 (Pr = 0.14 | P = 0.02), ELME000173,-
MYO7A_HUMAN,M1734A,0.553,Altered Disordered interface (Pr = 0.29 | P = 0.01), None,-
MYO7A_HUMAN,V1735S,0.412,-,-,-
MYO7A_HUMAN,K1737R,0.222,-,-,-
MYO7A_HUMAN,K1741A,0.684,Altered Disordered interface (Pr = 0.37 | P = 8.3e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,R1743H,0.176,-,-,-
MYO7A_HUMAN,W1745G,0.881,Gain of Intrinsic disorder (Pr = 0.55 | P = 7.6e-04); Altered Disordered interface (Pr = 0.40 | P = 6.8e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.03), ELME000173,-
MYO7A_HUMAN,S1746A,0.196,-,-,-
MYO7A_HUMAN,T1748C,0.634,Altered Disordered interface (Pr = 0.29 | P = 0.01); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.04), ELME000173,-
MYO7A_HUMAN,L1756A,0.790,Altered Stability (Pr = 0.38 | P = 3.3e-03), ELME000045|ELME000146,-
MYO7A_HUMAN,L1756C,0.839,Altered Stability (Pr = 0.13 | P = 0.03), ELME000045|ELME000146,-
MYO7A_HUMAN,K1759G,0.627,, ELME000045|ELME000106|ELME000146|PS00008,-
MYO7A_HUMAN,L1760V,0.141,-,-,-
MYO7A_HUMAN,E1764P,0.405,-,-,-
MYO7A_HUMAN,E1765A,0.518,, ELME000053|ELME000202,-
MYO7A_HUMAN,A1770P,0.945,, ELME000202,-
MYO7A_HUMAN,C1771L,0.951,, None,-
MYO7A_HUMAN,F1774P,0.943,Gain of Acetylation at K1779 (Pr = 0.22 | P = 0.03), ELME000041,-
MYO7A_HUMAN,L1778I,0.447,-,-,-
MYO7A_HUMAN,K1779G,0.915,Loss of Acetylation at K1779 (Pr = 0.25 | P = 0.01); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of Allosteric site at Y1780 (Pr = 0.23 | P = 0.02); Gain of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.04), ELME000041,-
MYO7A_HUMAN,S1786H,0.722,Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Ubiquitylation at K1787 (Pr = 0.15 | P = 0.05); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000063|ELME000271|ELME000334|PS00005,-
MYO7A_HUMAN,K1787G,0.861,Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of ADP-ribosylation at R1790 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K1787 (Pr = 0.18 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.03); Loss of Proteolytic cleavage at D1783 (Pr = 0.11 | P = 0.05), ELME000052|ELME000063|ELME000085|ELME000100|ELME000108|ELME000271|PS00005,-
MYO7A_HUMAN,T1789M,0.137,-,-,-
MYO7A_HUMAN,A1813V,0.190,-,-,-
MYO7A_HUMAN,I1817V,0.216,-,-,-
MYO7A_HUMAN,H1825N,0.503,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,Y1828S,0.744,Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000062|ELME000064|ELME000117|PS00006,-
MYO7A_HUMAN,E1830T,0.859,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Ordered interface (Pr = 0.23 | P = 0.05); Altered Transmembrane protein (Pr = 0.09 | P = 0.05), ELME000062|ELME000334|PS00005,-
MYO7A_HUMAN,E1831D,0.550,Gain of Allosteric site at W1834 (Pr = 0.20 | P = 0.04); Gain of Sulfation at Y1828 (Pr = 0.01 | P = 0.05), ELME000062,-
MYO7A_HUMAN,N1848V,0.671,, ELME000335,-
MYO7A_HUMAN,I1849S,0.607,Altered Stability (Pr = 0.13 | P = 0.03), ELME000239,-
MYO7A_HUMAN,R1856V,0.593,, None,-
MYO7A_HUMAN,F1857L,0.785,, ELME000336|PS00029,-
MYO7A_HUMAN,H1863Q,0.381,-,-,-
MYO7A_HUMAN,C1864S,0.242,-,-,-
MYO7A_HUMAN,L1871V,0.220,-,-,-
MYO7A_HUMAN,L1874P,0.944,Loss of Acetylation at K1876 (Pr = 0.19 | P = 0.05); Altered DNA binding (Pr = 0.17 | P = 0.03); Altered Stability (Pr = 0.17 | P = 0.02); Altered Coiled coil (Pr = 0.15 | P = 0.03), ELME000134|ELME000313,-
MYO7A_HUMAN,D1910E,0.543,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Metal binding (Pr = 0.26 | P = 0.02), ELME000182,-
MYO7A_HUMAN,A1915H,0.761,Altered Metal binding (Pr = 0.52 | P = 4.3e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered Stability (Pr = 0.25 | P = 7.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04), None,-
MYO7A_HUMAN,A1915S,0.388,-,-,-
MYO7A_HUMAN,E1917Q,0.680,Altered Metal binding (Pr = 0.30 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered DNA binding (Pr = 0.17 | P = 0.04); Altered Stability (Pr = 0.11 | P = 0.04), None,-
MYO7A_HUMAN,T1922S,0.751,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.02); Gain of B-factor (Pr = 0.27 | P = 8.6e-03); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.18 | P = 0.03), PS00005,-
MYO7A_HUMAN,T1922V,0.883,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000147|PS00005,-
MYO7A_HUMAN,K1923D,0.668,Altered Metal binding (Pr = 0.35 | P = 5.0e-04); Altered Ordered interface (Pr = 0.30 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.04); Altered DNA binding (Pr = 0.20 | P = 0.02), ELME000321|PS00005|PS00006,-
MYO7A_HUMAN,A1924C,0.858,Altered Metal binding (Pr = 0.46 | P = 6.0e-03); Altered Ordered interface (Pr = 0.32 | P = 9.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered DNA binding (Pr = 0.19 | P = 0.03), ELME000313,-
MYO7A_HUMAN,D1926F,0.929,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.18 | P = 0.03), ELME000313,-
